Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.

Author information

Affiliations

  • 1. Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
      Authors
    • Wang Y 1, 3
    • Li N 1
    • Qiao Y 1
    • Sharma A 1
    • Lin SH 1, 2
    (5 authors)
  • 2. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
      Authors
    • Jiang W 2
    • Deng W 2
    • Lin SH 1, 2
    (3 authors)
  • 3. The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas.
      Authors
    • Wang Y 1, 3
    • Ye R 3
    (2 authors)
  • 4. Department of Radiation Oncology, Tianjin Medical University Cancer Hospital, Tianjin, China.
      Authors
    • Xu C 4
    (1 author)
  • 5. Department of Radiation Oncology, Hebei General Hospital, Shijiazhuang, Hebei, China.
      Authors
    • Zhang M 5
    (1 author)
    • Show all (6)

ORCIDs linked to this article

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 01 Aug 2018, 24(22):5744-5756
https://doi.org/10.1158/1078-0432.ccr-18-1489 PMID: 30068711 

Abstract 

Purpose: The MEK inhibitor trametinib radiosensitizes KRAS-mutant non-small cell lung cancer (NSCLC) and is being tested clinically with chemoradiation. However, variability in response to trametinib suggests that additional pathways are involved. The mechanism of resistance to trametinib radiosensitization is still unknown.Experimental Design: We used a panel of KRAS-mutant NSCLC cells and tested the radiosensitization effects of trametinib by clonogenic survival assay. Then, we investigated the mechanisms underlying the resistance to the combination therapy through several knockout and overexpression systems. Finally, we validated our findings in syngeneic mouse models in a treatment setting that mimicked the standard of care in the clinic.Results: Radiosensitization by trametinib was effective only in KRAS-LKB1-mutated cells with wild-type (WT) p53, and we found that restoring LKB1 expression in those cells blocked that sensitization. Trametinib and radiotherapy both induced senescence in a p53-dependent manner, but in WT LKB1 cells, the combination also activated the AMPK-autophagy pathway to rescue damaged cells from senescence. LKB1-knockout or autophagy inhibition in WT LKB1 cells potentiated trametinib radiosensitization. In syngeneic animal models of Kras-mutant lung tumors, Lkb1-knockout tumors were resistant to trametinib and chemoradiation given separately, but the combination greatly controlled tumor growth and prolonged survival.Conclusions: The LKB1 mutation in KRAS-mutant NSCLC conferred enhanced radiosensitization in combination with trametinib. The WT LKB1 could activate autophagy through AMPK pathway to induce resistance to the combination of trametinib and radiation. The KRAS-LKB1 mutation could potentially be a biomarker to select patients for trametinib and radiotherapy combination therapy. Clin Cancer Res; 24(22); 5744-56. ©2018 AACR.

Full text links 

Read article at publisher's site: https://doi.org/10.1158/1078-0432.ccr-18-1489

Read article for free, from open access legal sources, via Unpaywall: https://aacr.figshare.com/ndownloader/files/39921219Unpaywall

Citations & impact 

Impact metrics

23
Citations
Jump to Citations
10
Data citations
Jump to Data

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/45913084
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/45913084

Article citations

Go to all (23) article citations

Data 

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

CORE (1)

NIH NCI (1)